The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells

The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells

Background: The third-generation epidermal growth factor receptor (EGFR) inhibitor, Osimertinib, is used to treat non-small cell lung cancer (NSCLC) patients with tyrosine kinase inhibitor (TKI) resistance caused by acquired EGFR T790M mutation. However, patients eventually develop resistance agains...

Full description

Bibliographic Details
Main Authors:	Wen-Chien Huang, Vijesh Kumar Yadav, Wei-Hong Cheng, Chun-Hua Wang, Ming-Shou Hsieh, Ting-Yi Huang, Shiou-Fu Lin, Chi-Tai Yeh, Kuang-Tai Kuo
Format:	Article
Language:	English
Published:	MDPI AG 2021-11-01
Series:	Cancers
Subjects:	non-small cell lung cancer (NSCLC) Osimertinib resistance MEK inhibitor Trametinib miR-21 cancer-associated fibroblasts (CAFs) human lung fibroblasts (HLFs)
Online Access:	https://www.mdpi.com/2072-6694/13/23/6005

Similar Items

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
by: Weart TC, et al.
Published: (2018-04-01)

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
by: Yu D, et al.
Published: (2021-02-01)

BRAF Inhibitors in Non-Small Cell Lung Cancer
by: Vincenzo Sforza, et al.
Published: (2022-10-01)

Midazolam impedes lung carcinoma cell proliferation and migration via EGFR/MEK/ERK signaling pathway
by: Zhang Xiangchao, et al.
Published: (2023-06-01)

Osimertinib for the first-line treatment of EGFR-positive non-small cell lung cancer
by: Elena V Reutova, et al.
Published: (2019-09-01)

SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC
by: Man Yuan, et al.
Published: (2019-07-01)

The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway
by: Juri Ogishima, et al.
Published: (2018-12-01)

Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer
by: Steven H Lin, et al.
Published: (2022-01-01)

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
by: Chul Kim, et al.
Published: (2021-09-01)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
by: Hongjing Zang, et al.
Published: (2020-04-01)

Evidence of steady-state fibroblast subtypes in the normal human breast as cells-of-origin for perturbed-state fibroblasts in breast cancer
by: Mikkel Morsing Bagger, et al.
Published: (2024-01-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
by: Jiao‐Li Wang, et al.
Published: (2022-11-01)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
by: Zentaro Saito, et al.
Published: (2023-10-01)

Extracellular Citrate Fuels Cancer Cell Metabolism and Growth
by: Sebastian Haferkamp, et al.
Published: (2020-12-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
by: K. Haslett, et al.
Published: (2021-05-01)

Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer
by: Yingying Jiang, et al.
Published: (2022-06-01)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
by: Stefanie Hoyer, et al.
Published: (2021-11-01)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022-01-01)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
by: Bora Lim, et al.
Published: (2021-10-01)

Response to Osimertinib in a Patient with Non-Small Cell Lung Cancer and Two Uncommon EGFR Mutations
by: Christoforos Astaras, et al.
Published: (2020-03-01)

MEK inhibitors for the treatment of extracranial arteriovenous malformations
by: Zi’an Xu, et al.
Published: (2023-09-01)

Successful osimertinib retreatment after extremely early onset severe pneumonitis in first‐line treatment of lung adenocarcinoma
by: June Hong Ahn
Published: (2020-09-01)

Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer
by: Hye Sook Kim, et al.
Published: (2023-06-01)

Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
by: Oliver Gautschi, MD, et al.
Published: (2021-04-01)

An Overview of the Role of Mechanical Stretching in the Progression of Lung Cancer
by: Fengying Gong, et al.
Published: (2021-12-01)

Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion
by: Ayu Kiritani, et al.
Published: (2024-02-01)

A case report: Response to Osimertinib in non-small cell lung cancer patient with uncommon EGFR mutation
by: Daniel J. Craig, et al.
Published: (2022-12-01)

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
by: Yufeng Li, et al.
Published: (2023-04-01)

Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum
by: David M. Gershenson, et al.
Published: (2020-11-01)

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy
by: K. A. Sarantseva, et al.
Published: (2020-12-01)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
by: Sergey V. Goryaynov
Published: (2021-11-01)

Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib
by: Carolien Eggermont, et al.
Published: (2023-05-01)

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review
by: Chihiro Maeda, et al.
Published: (2023-10-01)

Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report
by: Junjie GU, et al.
Published: (2021-11-01)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
by: Fionnuala Crowley, MB BCh BAO, et al.
Published: (2022-01-01)

Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development
by: Anna Valeria Samarelli, et al.
Published: (2021-11-01)

Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer
by: Xueli Tian, et al.
Published: (2022-10-01)

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer
by: Takehiro Tozuka, et al.
Published: (2023-09-01)

Salidroside represses proliferation, migration and invasion of human lung cancer cells through AKT and MEK/ERK signal pathway
by: Mei Ren, et al.
Published: (2019-12-01)